The GLP-1 Revolution: How The Trump’s Pricing Deal Impacts Eli Lilly, Novo Nordisk, and Beyond
The November 2025 GLP-1 pricing deal cut list prices by up to 85%. What it does to Eli Lilly and Novo Nordisk economics, and to patient access.
Tag: VBM Context
